MAYNE PHARMA GROUP LIMITED - Announcements

3.88%

$4.95

Market Cap $402.1M

Healthcare Drug Manufacturers - Specialty & Generic

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused... Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) accelerates commercialisation with positive Phase II results.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

MYX	Results of Scheme Meeting	PRICE SENSITIVE	18/06/25	299.54KB	Share
MYX	Chair's address and presentation at the Scheme Meeting	PRICE SENSITIVE	18/06/25	977.95KB	Share
MYX	Update on litigation with Cosette	PRICE SENSITIVE	16/06/25	136.36KB	Share
MYX	Supplementary Scheme Booklet	PRICE SENSITIVE	05/06/25	254.59KB	Share
MYX	Mayne Pharma receives purported notice to terminate SID	PRICE SENSITIVE	04/06/25	117KB	Share
MYX	Update on Scheme of Arrangement with Cosette	PRICE SENSITIVE	04/06/25	115.79KB	Share
MYX	Response to ASX Aware Letter	PRICE SENSITIVE	22/05/25	475.81KB	Share
MYX	Update on Scheme with Cosette	PRICE SENSITIVE	21/05/25	119.12KB	Share
MYX	Trading Halt	PRICE SENSITIVE	19/05/25	260.12KB	Share
MYX	ASIC registration of Mayne Pharma scheme booklet	PRICE SENSITIVE	15/05/25	4.28MB	Share
MYX	Court approves convening of scheme meeting	PRICE SENSITIVE	15/05/25	113.92KB	Share
MYX	Response to ASX Price Query	PRICE SENSITIVE	14/05/25	405.11KB	Share
MYX	Pause in Trade	PRICE SENSITIVE	14/05/25	116.24KB	Share
MYX	Response to ASX Query	PRICE SENSITIVE	12/05/25	405.81KB	Share
MYX	2025 Half Year Investor Presentation	PRICE SENSITIVE	26/02/25	1023.58KB	Share
MYX	2025 Half Year Media Release	PRICE SENSITIVE	26/02/25	367.46KB	Share
MYX	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/25	1.16MB	Share
MYX	Mayne Pharma enters Scheme Implementation Deed with Cosette	PRICE SENSITIVE	21/02/25	1.44MB	Share
MYX	Mayne Pharma market update	PRICE SENSITIVE	10/02/25	151.78KB	Share
MYX	2024 AGM presentation and business update	PRICE SENSITIVE	21/11/24	1.2MB	Share
MYX	2024 Full Year Results Investor Presentation	PRICE SENSITIVE	23/08/24	1.21MB	Share
MYX	2024 Full Year Results Media Release	PRICE SENSITIVE	23/08/24	383.94KB	Share
MYX	Appendix 4E and Full Year Statutory Accounts	PRICE SENSITIVE	23/08/24	2.32MB	Share
MYX	Class action settlement	PRICE SENSITIVE	02/07/24	90.31KB	Share
MYX	Notification of buy-back - MYX	PRICE SENSITIVE	24/05/24	13.03KB	Share
MYX	2024 Half Year Investor Presentation	PRICE SENSITIVE	26/02/24	1.1MB	Share
MYX	2024 Half Year Media Release	PRICE SENSITIVE	26/02/24	337.33KB	Share
MYX	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/24	1.3MB	Share
MYX	Issuance of additional US Patent for NEXTSTELLIS	PRICE SENSITIVE	06/11/23	124.22KB	Share
MYX	Mayne Pharma provides update on 1Q FY24 trading and outlook	PRICE SENSITIVE	18/10/23	969.53KB	Share
MYX	2023 Full Year Results Investor Presentation	PRICE SENSITIVE	31/08/23	1.07MB	Share
MYX	2023 Full Year Results Media Release	PRICE SENSITIVE	31/08/23	159.25KB	Share
MYX	Preliminary Final Report	PRICE SENSITIVE	31/08/23	1.23MB	Share
MYX	Mayne Pharma May 2023 market update presentation	PRICE SENSITIVE	10/05/23	1.26MB	Share
MYX	MYX provides investor update & announces on market buyback	PRICE SENSITIVE	10/05/23	175.1KB	Share
MYX	MYX completes sale of US retail generics business for US$90m	PRICE SENSITIVE	11/04/23	126.41KB	Share
MYX	Update on sale of US retail generics portfolio	PRICE SENSITIVE	03/04/23	90.76KB	Share
MYX	Mayne Pharma announces cancellation of capital return	PRICE SENSITIVE	28/02/23	88.17KB	Share
MYX	2023 Half Year Investor Presentation	PRICE SENSITIVE	28/02/23	2.17MB	Share
MYX	2022 Half Year Media Release	PRICE SENSITIVE	28/02/23	188.04KB	Share
MYX	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	1.25MB	Share
MYX	Mayne Pharma announces sale of US retail generics business	PRICE SENSITIVE	27/02/23	152.88KB	Share
MYX	Trading Halt	PRICE SENSITIVE	27/02/23	248.55KB	Share
MYX	Pause in Trading	PRICE SENSITIVE	27/02/23	117.29KB	Share
MYX	Mayne Pharma to restate US dermatology net revenue for FY22	PRICE SENSITIVE	15/02/23	126.64KB	Share
MYX	Mayne Pharma provides update on capital management timeline	PRICE SENSITIVE	12/01/23	151.54KB	Share
MYX	MYX completes TherapeuticsMD product licensing transaction	PRICE SENSITIVE	03/01/23	108.26KB	Share
MYX	MYX signs license agreement for women's health products	PRICE SENSITIVE	05/12/22	186.17KB	Share
MYX	AGM presentation and business and trading update	PRICE SENSITIVE	30/11/22	985.21KB	Share
MYX	Return of Capital - MYX	PRICE SENSITIVE	28/10/22	151.27KB	Share
MYX	Dividend/Distribution - MYX	PRICE SENSITIVE	28/10/22	194KB	Share
MYX	Mayne Pharma capital management update	PRICE SENSITIVE	28/10/22	156.76KB	Share
MYX	Mayne Pharma completes sale of Metrics Contract Services	PRICE SENSITIVE	04/10/22	162.72KB	Share
MYX	Mayne Pharma appoints new CEO	PRICE SENSITIVE	28/09/22	160.07KB	Share
MYX	2022 Full Year Investor Presentation	PRICE SENSITIVE	26/08/22	2.74MB	Share
MYX	2022 Full Year Media Release	PRICE SENSITIVE	26/08/22	393.2KB	Share
MYX	Appendix 4E and Statutory Accounts	PRICE SENSITIVE	26/08/22	2.08MB	Share
MYX	Mayne Pharma CEO announces plan to retire	PRICE SENSITIVE	19/08/22	147.48KB	Share
MYX	Mayne Pharma announces sale of Metrics Contract Services	PRICE SENSITIVE	10/08/22	189.91KB	Share
MYX	Mayne Pharma recipient of $4.8m Federal Government Grant	PRICE SENSITIVE	09/05/22	95.11KB	Share
MYX	2022 Half Year Investor Presentation	PRICE SENSITIVE	25/02/22	1.71MB	Share
MYX	2022 Half Year Media Release	PRICE SENSITIVE	25/02/22	323.7KB	Share
MYX	Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/22	4.6MB	Share
MYX	Mayne Pharma expands US dermatology portfolio	PRICE SENSITIVE	10/02/22	94.58KB	Share
MYX	2021 Mayne Pharma AGM Speeches	PRICE SENSITIVE	23/11/21	948.24KB	Share
MYX	2021 Full Year Investor Presentation	PRICE SENSITIVE	27/08/21	1.13MB	Share
MYX	2021 Full Year Media Release	PRICE SENSITIVE	27/08/21	395.94KB	Share
MYX	Appendix 4E and Statutory Accounts	PRICE SENSITIVE	27/08/21	1.97MB	Share
MYX	Class action proceeding	PRICE SENSITIVE	03/08/21	114.64KB	Share
MYX	FDA approval of novel oral contraceptive NEXTSTELLIS	PRICE SENSITIVE	16/04/21	123.85KB	Share
MYX	2021 Half Year Investor Presentation	PRICE SENSITIVE	24/02/21	2.76MB	Share
MYX	2021 Half Year Media Release	PRICE SENSITIVE	24/02/21	314.02KB	Share
MYX	Half Yearly Report and Accounts	PRICE SENSITIVE	24/02/21	1.76MB	Share
MYX	Chairman and CEO's Addresses to Shareholders	PRICE SENSITIVE	24/11/20	3.27MB	Share
MYX	Mayne Pharma provides update on Women's Health pipeline	PRICE SENSITIVE	06/10/20	153.98KB	Share
MYX	2020 Full Year Investor Presentation	PRICE SENSITIVE	21/08/20	6.13MB	Share
MYX	2020 Full Year Media Release	PRICE SENSITIVE	21/08/20	404.79KB	Share
MYX	Appendix 4E and Statutory Accounts	PRICE SENSITIVE	21/08/20	1.59MB	Share
MYX	Mayne Pharma announces strategic partnership with Novast	PRICE SENSITIVE	06/07/20	158.24KB	Share
MYX	MYX announces FDA filing acceptance of E4/DRSP in the US	PRICE SENSITIVE	24/06/20	149.82KB	Share
MYX	S&P DJI Announces June 2020 Quarterly Rebalance	PRICE SENSITIVE	12/06/20	223.16KB	Share
MYX	MYX signs license agreement for contraceptive in Australia	PRICE SENSITIVE	28/05/20	150.15KB	Share
MYX	Mayne Pharma submits NDA for E4/DRSP to the FDA	PRICE SENSITIVE	16/04/20	121.21KB	Share
MYX	2020 Half Year Investor Presentation	PRICE SENSITIVE	21/02/20	3.5MB	Share
MYX	2020 Half Year Media Release	PRICE SENSITIVE	21/02/20	325.33KB	Share
MYX	Half Yearly Report and Accounts	PRICE SENSITIVE	21/02/20	1.11MB	Share
MYX	2019 AGM CEO's Speech	PRICE SENSITIVE	22/11/19	138.92KB	Share
MYX	E4/DRSP contraceptive presented at EU gynecology conference	PRICE SENSITIVE	23/10/19	110.39KB	Share
MYX	MYX signs license agreement for novel oral contraceptive	PRICE SENSITIVE	02/10/19	126.01KB	Share
MYX	2019 Full Year Results Investor Presentation	PRICE SENSITIVE	23/08/19	1.14MB	Share
MYX	2019 Full Year Results Media Release	PRICE SENSITIVE	23/08/19	174.98KB	Share
MYX	Appendix 4E and Full Year Statutory Accounts	PRICE SENSITIVE	23/08/19	1.71MB	Share
MYX	Mayne Pharma market update	PRICE SENSITIVE	14/05/19	286.05KB	Share
MYX	2019 Half Year Investor Presentation	PRICE SENSITIVE	22/02/19	1.44MB	Share
MYX	2019 Half Year Media Release	PRICE SENSITIVE	22/02/19	439.98KB	Share
MYX	Half Year Accounts	PRICE SENSITIVE	22/02/19	1.44MB	Share
MYX	Tolsura (SUBA-itraconazole) capsule now launched in the US	PRICE SENSITIVE	30/01/19	455.75KB	Share
MYX	FDA approval of Tolsura (SUBA-itraconazole) capsules	PRICE SENSITIVE	12/12/18	409.5KB	Share
MYX	2018 AGM CEO's Speech	PRICE SENSITIVE	29/11/18	256.36KB	Share
MYX	2018 AGM Chairman's Address	PRICE SENSITIVE	29/11/18	257.21KB	Share

MYX Results of Scheme Meeting
18/06/25	PRICE SENSITIVE	299.54KB	Share
MYX Chair's address and presentation at the Scheme Meeting
18/06/25	PRICE SENSITIVE	977.95KB	Share
MYX Update on litigation with Cosette
16/06/25	PRICE SENSITIVE	136.36KB	Share
MYX Supplementary Scheme Booklet
05/06/25	PRICE SENSITIVE	254.59KB	Share
MYX Mayne Pharma receives purported notice to terminate SID
04/06/25	PRICE SENSITIVE	117KB	Share
MYX Update on Scheme of Arrangement with Cosette
04/06/25	PRICE SENSITIVE	115.79KB	Share
MYX Response to ASX Aware Letter
22/05/25	PRICE SENSITIVE	475.81KB	Share
MYX Update on Scheme with Cosette
21/05/25	PRICE SENSITIVE	119.12KB	Share
MYX Trading Halt
19/05/25	PRICE SENSITIVE	260.12KB	Share
MYX ASIC registration of Mayne Pharma scheme booklet
15/05/25	PRICE SENSITIVE	4.28MB	Share
MYX Court approves convening of scheme meeting
15/05/25	PRICE SENSITIVE	113.92KB	Share
MYX Response to ASX Price Query
14/05/25	PRICE SENSITIVE	405.11KB	Share
MYX Pause in Trade
14/05/25	PRICE SENSITIVE	116.24KB	Share
MYX Response to ASX Query
12/05/25	PRICE SENSITIVE	405.81KB	Share
MYX 2025 Half Year Investor Presentation
26/02/25	PRICE SENSITIVE	1023.58KB	Share
MYX 2025 Half Year Media Release
26/02/25	PRICE SENSITIVE	367.46KB	Share
MYX Half Yearly Report and Accounts
26/02/25	PRICE SENSITIVE	1.16MB	Share
MYX Mayne Pharma enters Scheme Implementation Deed with Cosette
21/02/25	PRICE SENSITIVE	1.44MB	Share
MYX Mayne Pharma market update
10/02/25	PRICE SENSITIVE	151.78KB	Share
MYX 2024 AGM presentation and business update
21/11/24	PRICE SENSITIVE	1.2MB	Share
MYX 2024 Full Year Results Investor Presentation
23/08/24	PRICE SENSITIVE	1.21MB	Share
MYX 2024 Full Year Results Media Release
23/08/24	PRICE SENSITIVE	383.94KB	Share
MYX Appendix 4E and Full Year Statutory Accounts
23/08/24	PRICE SENSITIVE	2.32MB	Share
MYX Class action settlement
02/07/24	PRICE SENSITIVE	90.31KB	Share
MYX Notification of buy-back - MYX
24/05/24	PRICE SENSITIVE	13.03KB	Share
MYX 2024 Half Year Investor Presentation
26/02/24	PRICE SENSITIVE	1.1MB	Share
MYX 2024 Half Year Media Release
26/02/24	PRICE SENSITIVE	337.33KB	Share
MYX Half Yearly Report and Accounts
26/02/24	PRICE SENSITIVE	1.3MB	Share
MYX Issuance of additional US Patent for NEXTSTELLIS
06/11/23	PRICE SENSITIVE	124.22KB	Share
MYX Mayne Pharma provides update on 1Q FY24 trading and outlook
18/10/23	PRICE SENSITIVE	969.53KB	Share
MYX 2023 Full Year Results Investor Presentation
31/08/23	PRICE SENSITIVE	1.07MB	Share
MYX 2023 Full Year Results Media Release
31/08/23	PRICE SENSITIVE	159.25KB	Share
MYX Preliminary Final Report
31/08/23	PRICE SENSITIVE	1.23MB	Share
MYX Mayne Pharma May 2023 market update presentation
10/05/23	PRICE SENSITIVE	1.26MB	Share
MYX MYX provides investor update & announces on market buyback
10/05/23	PRICE SENSITIVE	175.1KB	Share
MYX MYX completes sale of US retail generics business for US$90m
11/04/23	PRICE SENSITIVE	126.41KB	Share
MYX Update on sale of US retail generics portfolio
03/04/23	PRICE SENSITIVE	90.76KB	Share
MYX Mayne Pharma announces cancellation of capital return
28/02/23	PRICE SENSITIVE	88.17KB	Share
MYX 2023 Half Year Investor Presentation
28/02/23	PRICE SENSITIVE	2.17MB	Share
MYX 2022 Half Year Media Release
28/02/23	PRICE SENSITIVE	188.04KB	Share
MYX Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	1.25MB	Share
MYX Mayne Pharma announces sale of US retail generics business
27/02/23	PRICE SENSITIVE	152.88KB	Share
MYX Trading Halt
27/02/23	PRICE SENSITIVE	248.55KB	Share
MYX Pause in Trading
27/02/23	PRICE SENSITIVE	117.29KB	Share
MYX Mayne Pharma to restate US dermatology net revenue for FY22
15/02/23	PRICE SENSITIVE	126.64KB	Share
MYX Mayne Pharma provides update on capital management timeline
12/01/23	PRICE SENSITIVE	151.54KB	Share
MYX MYX completes TherapeuticsMD product licensing transaction
03/01/23	PRICE SENSITIVE	108.26KB	Share
MYX MYX signs license agreement for women's health products
05/12/22	PRICE SENSITIVE	186.17KB	Share
MYX AGM presentation and business and trading update
30/11/22	PRICE SENSITIVE	985.21KB	Share
MYX Return of Capital - MYX
28/10/22	PRICE SENSITIVE	151.27KB	Share
MYX Dividend/Distribution - MYX
28/10/22	PRICE SENSITIVE	194KB	Share
MYX Mayne Pharma capital management update
28/10/22	PRICE SENSITIVE	156.76KB	Share
MYX Mayne Pharma completes sale of Metrics Contract Services
04/10/22	PRICE SENSITIVE	162.72KB	Share
MYX Mayne Pharma appoints new CEO
28/09/22	PRICE SENSITIVE	160.07KB	Share
MYX 2022 Full Year Investor Presentation
26/08/22	PRICE SENSITIVE	2.74MB	Share
MYX 2022 Full Year Media Release
26/08/22	PRICE SENSITIVE	393.2KB	Share
MYX Appendix 4E and Statutory Accounts
26/08/22	PRICE SENSITIVE	2.08MB	Share
MYX Mayne Pharma CEO announces plan to retire
19/08/22	PRICE SENSITIVE	147.48KB	Share
MYX Mayne Pharma announces sale of Metrics Contract Services
10/08/22	PRICE SENSITIVE	189.91KB	Share
MYX Mayne Pharma recipient of $4.8m Federal Government Grant
09/05/22	PRICE SENSITIVE	95.11KB	Share
MYX 2022 Half Year Investor Presentation
25/02/22	PRICE SENSITIVE	1.71MB	Share
MYX 2022 Half Year Media Release
25/02/22	PRICE SENSITIVE	323.7KB	Share
MYX Half Yearly Report and Accounts
25/02/22	PRICE SENSITIVE	4.6MB	Share
MYX Mayne Pharma expands US dermatology portfolio
10/02/22	PRICE SENSITIVE	94.58KB	Share
MYX 2021 Mayne Pharma AGM Speeches
23/11/21	PRICE SENSITIVE	948.24KB	Share
MYX 2021 Full Year Investor Presentation
27/08/21	PRICE SENSITIVE	1.13MB	Share
MYX 2021 Full Year Media Release
27/08/21	PRICE SENSITIVE	395.94KB	Share
MYX Appendix 4E and Statutory Accounts
27/08/21	PRICE SENSITIVE	1.97MB	Share
MYX Class action proceeding
03/08/21	PRICE SENSITIVE	114.64KB	Share
MYX FDA approval of novel oral contraceptive NEXTSTELLIS
16/04/21	PRICE SENSITIVE	123.85KB	Share
MYX 2021 Half Year Investor Presentation
24/02/21	PRICE SENSITIVE	2.76MB	Share
MYX 2021 Half Year Media Release
24/02/21	PRICE SENSITIVE	314.02KB	Share
MYX Half Yearly Report and Accounts
24/02/21	PRICE SENSITIVE	1.76MB	Share
MYX Chairman and CEO's Addresses to Shareholders
24/11/20	PRICE SENSITIVE	3.27MB	Share
MYX Mayne Pharma provides update on Women's Health pipeline
06/10/20	PRICE SENSITIVE	153.98KB	Share
MYX 2020 Full Year Investor Presentation
21/08/20	PRICE SENSITIVE	6.13MB	Share
MYX 2020 Full Year Media Release
21/08/20	PRICE SENSITIVE	404.79KB	Share
MYX Appendix 4E and Statutory Accounts
21/08/20	PRICE SENSITIVE	1.59MB	Share
MYX Mayne Pharma announces strategic partnership with Novast
06/07/20	PRICE SENSITIVE	158.24KB	Share
MYX MYX announces FDA filing acceptance of E4/DRSP in the US
24/06/20	PRICE SENSITIVE	149.82KB	Share
MYX S&P DJI Announces June 2020 Quarterly Rebalance
12/06/20	PRICE SENSITIVE	223.16KB	Share
MYX MYX signs license agreement for contraceptive in Australia
28/05/20	PRICE SENSITIVE	150.15KB	Share
MYX Mayne Pharma submits NDA for E4/DRSP to the FDA
16/04/20	PRICE SENSITIVE	121.21KB	Share
MYX 2020 Half Year Investor Presentation
21/02/20	PRICE SENSITIVE	3.5MB	Share
MYX 2020 Half Year Media Release
21/02/20	PRICE SENSITIVE	325.33KB	Share
MYX Half Yearly Report and Accounts
21/02/20	PRICE SENSITIVE	1.11MB	Share
MYX 2019 AGM CEO's Speech
22/11/19	PRICE SENSITIVE	138.92KB	Share
MYX E4/DRSP contraceptive presented at EU gynecology conference
23/10/19	PRICE SENSITIVE	110.39KB	Share
MYX MYX signs license agreement for novel oral contraceptive
02/10/19	PRICE SENSITIVE	126.01KB	Share
MYX 2019 Full Year Results Investor Presentation
23/08/19	PRICE SENSITIVE	1.14MB	Share
MYX 2019 Full Year Results Media Release
23/08/19	PRICE SENSITIVE	174.98KB	Share
MYX Appendix 4E and Full Year Statutory Accounts
23/08/19	PRICE SENSITIVE	1.71MB	Share
MYX Mayne Pharma market update
14/05/19	PRICE SENSITIVE	286.05KB	Share
MYX 2019 Half Year Investor Presentation
22/02/19	PRICE SENSITIVE	1.44MB	Share
MYX 2019 Half Year Media Release
22/02/19	PRICE SENSITIVE	439.98KB	Share
MYX Half Year Accounts
22/02/19	PRICE SENSITIVE	1.44MB	Share
MYX Tolsura (SUBA-itraconazole) capsule now launched in the US
30/01/19	PRICE SENSITIVE	455.75KB	Share
MYX FDA approval of Tolsura (SUBA-itraconazole) capsules
12/12/18	PRICE SENSITIVE	409.5KB	Share
MYX 2018 AGM CEO's Speech
29/11/18	PRICE SENSITIVE	256.36KB	Share
MYX 2018 AGM Chairman's Address
29/11/18	PRICE SENSITIVE	257.21KB	Share

REFRESH

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $4.95		Change -0.200(3.88%)		Mkt cap ! $402.1M

Open	High	Low	Value	Volume
$5.05	$5.09	$4.93	$824.9K	165.3K

Buyers (Bids)

No.	Vol.	Price($)
1	16429	$4.95

Sellers (Offers)

Price($)	Vol.	No.
$5.08	5000	1

View Market Depth

No.	Vol.	Price($)
1	16429	4.950
1	3583	4.940
1	5000	4.930
1	2745	4.920
2	1849	4.910

Price($)	Vol.	No.
5.080	5000	1
5.100	10000	1
5.120	3630	2
5.180	2200	1
5.210	1000	1

Last trade - 16.10pm 31/07/2025 (20 minute delay)


Last $4.95		Change -0.200 ( 3.52 %)
Open	High	Low	Volume
$5.07	$5.07	$4.94	15951
Last updated 15.59pm 31/07/2025 ?

MYX (ASX) Chart

MAYNE PHARMA GROUP LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

A new NASDAQ listing for a key player in the global critical minerals space

Top Stories